Retraction
Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells
Paper Information
Record ID:
29547
Author(s):
Journal:
Publication Date:
March 05, 2013
Retraction Date:
June 11, 2021
(4.4 years years ago)
Subjects:
Institutions:
- Division of Hematology-Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
- Division of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
- 330 Brookline Avenue, RW-571, Boston, MA, 02215, USA
- 330 Brookline Avenue, RW-563A, Boston, MA, 02215, USA
Countries:
Article Type:
Publisher:
Springer - Biomed Central (BMC)
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1186/s12943-021-01379-7Additional Notes:
David Panka has ORI finding of misconduct; see https://ori.hhs.gov/content/case-summary-panka-david;
Citations (35)
35
Total Citations3
Post-Retraction(8.6%)
32
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
2
Within 1 year
1
After 2+ years
937
Days since retraction (latest)
Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma
Xun Li, Chengcheng Zhang, Xiaotong Lin et al. (10 authors)
Experimental & Molecular Medicine
Open Access
Published: Jan 2024
13 citations
13 citations
937 days after retraction
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
Eric Jonasch, Michael B. Atkins, Simon Chowdhury et al. (4 authors)
Cancers
Open Access
Published: Jan 2022
19 citations
19 citations
230 days after retraction
Inflammation and tumor progression: signaling pathways and targeted intervention
Huakan Zhao, Lei Wu, Guifang Yan et al. (7 authors)
Signal Transduction and Targeted Therapy
Open Access
Published: Jul 2021
1819 citations
1819 citations
31 days after retraction
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment
Hui Qin Wang, Iain J. Mulford, Fiona A. Sharp et al. (20 authors)
Cancer Research
Open Access
Published: Jan 2021
46 citations
46 citations
135 days before retraction
STAT3 and p53: Dual Target for Cancer Therapy
Thu‐Huyen Pham, Hyo‐Min Park, Jinju Kim et al. (5 authors)
Biomedicines
Open Access
Published: Dec 2020
45 citations
45 citations
172 days before retraction
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
Nuray Erin, Jelena Grahovac, Anamaria Brozović et al. (4 authors)
Drug Resistance Updates
Open Access
Published: Jun 2020
415 citations
415 citations
356 days before retraction
The metabolic landscape of urological cancers: New therapeutic perspectives
Vera Miranda‐Gonçalves, Ana Lameirinhas, Rui Henrique et al. (5 authors)
Cancer Letters
Published: Mar 2020
24 citations
24 citations
464 days before retraction
Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes <i>p53</i> -deficient cancers to mTOR inhibition
Na Kong, Wei Tao, Xiang Ling et al. (14 authors)
Science Translational Medicine
Open Access
Published: Dec 2019
253 citations
253 citations
541 days before retraction
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
Chun-Hau Chen, Swati S. Bhasin, Prateek Khanna et al. (15 authors)
Oncogenesis
Open Access
Published: Feb 2019
21 citations
21 citations
840 days before retraction
Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
Hossam Kamli, Glenda C. Gobé, Li Li et al. (5 authors)
Journal of Kidney Cancer and VHL
Open Access
Published: Aug 2018
11 citations
11 citations
1036 days before retraction
Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma
Guillermo de Velasco, Stephanie A. Wankowicz, Russell W. Madison et al. (16 authors)
British Journal of Cancer
Open Access
Published: Apr 2018
39 citations
39 citations
1150 days before retraction
Vitamin�D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model
Ewa Maj, Beata Filip‐Psurska, Magdalena Milczarek et al. (6 authors)
International Journal of Oncology
Open Access
Published: Dec 2017
31 citations
31 citations
1274 days before retraction
Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult
Tyler J. Loftus, Alicia M. Mohr, Lyle L. Moldawer
Current Opinion in Hematology
Open Access
Published: Oct 2017
53 citations
53 citations
1337 days before retraction
Refractory Mechanisms
Mototsugu Oya, Toshiaki Shinojima, Ryuichi Mizuno
Springer eBooks
Published: Jan 2017
1622 days before retraction
Targeting Myeloid-Derived Suppressor Cells in Cancer
Waseem Q. Anani, Michael R. Shurin
Advances in experimental medicine and biology
Published: Jan 2017
50 citations
50 citations
1622 days before retraction
Estrogen-induced SDF-1α production promotes the progression of ER-negative breast cancer via the accumulation of MDSCs in the tumor microenvironment
Ouyang Liquan, Weilong Chang, Bin Fang et al. (6 authors)
Scientific Reports
Open Access
Published: Dec 2016
51 citations
51 citations
1634 days before retraction
The Sabotaging Role of Myeloid Cells in Anti‐Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia
Chunyan Li, Tao Liu, Alexandr V. Bazhin et al. (4 authors)
Journal of Cellular Physiology
Published: Dec 2016
22 citations
22 citations
1645 days before retraction
Sunitinib: the antiangiogenic effects and beyond
Zhonglin Hao, Ibrahim M. Sadek
OncoTargets and Therapy
Open Access
Published: Sep 2016
92 citations
92 citations
1744 days before retraction
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model
C. Marcela Díaz‐Montero, Frances Mao, John Barnard et al. (9 authors)
British Journal of Cancer
Open Access
Published: Aug 2016
41 citations
41 citations
1751 days before retraction
Novel drugs that target the metabolic reprogramming in renal cell cancer
Johannes C. van der Mijn, David J. Panka, Andrew K. Geissler et al. (5 authors)
Cancer & Metabolism
Open Access
Published: Jul 2016
70 citations
70 citations
1794 days before retraction
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma
André P. Fay, Guillermo de Velasco, Thai H. Ho et al. (15 authors)
Journal of the National Comprehensive Cancer Network
Open Access
Published: Jul 2016
37 citations
37 citations
1806 days before retraction
Improving cancer immunotherapy by targeting the STATe of MDSCs
Nienke de Haas, Coco de Koning, Lisanne M. Spilgies et al. (5 authors)
OncoImmunology
Open Access
Published: Jun 2016
57 citations
57 citations
1810 days before retraction
Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients
Robert Stoehr, Robert Stoehr, Antonia Wenners et al. (21 authors)
Oncogenesis
Open Access
Published: Feb 2016
4 citations
4 citations
1929 days before retraction
Targeting HIF2 in Clear Cell Renal Cell Carcinoma
Hyejin Cho, William G. Kaelin
Cold Spring Harbor Symposia on Quantitative Biology
Open Access
Published: Jan 2016
53 citations
53 citations
1988 days before retraction
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
Ksenija Asić
Critical Reviews in Oncology/Hematology
Published: Aug 2015
34 citations
34 citations
2131 days before retraction
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma
Aurélie Guislain, Jules Gadiot, Andrew Kaiser et al. (11 authors)
Cancer Immunology Immunotherapy
Open Access
Published: Jun 2015
103 citations
103 citations
2180 days before retraction
Myeloid-Derived Suppressor Cells
Katherine H. Parker, Daniel W. Beury, Suzanne Ostrand‐Rosenberg
Advances in cancer research
Open Access
Published: Jan 2015
455 citations
455 citations
2353 days before retraction
Immunomodulation of myeloid-derived suppressor cells by particulate b-glucan in cancer.
Sabrin Albeituni
Unknown Journal
Open Access
Published: Jan 2015
2353 days before retraction
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives
Sophie C. Joosten, Lisanne C. Hamming, Patricia M.M.B. Soetekouw et al. (7 authors)
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Published: Nov 2014
108 citations
108 citations
2404 days before retraction
Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance
James W. Mier, Rupal S. Bhatt, David J. Panka et al. (4 authors)
Springer eBooks
Published: Nov 2014
2414 days before retraction
The multifaceted activity of VEGF in angiogenesis – Implications for therapy responses
Stijn Moens, Jermaine Goveia, Peter C. Stapor et al. (5 authors)
Cytokine & Growth Factor Reviews
Published: Jul 2014
151 citations
151 citations
2515 days before retraction
Impact of myeloid cells on the efficacy of anticancer chemotherapy
Laura Senovilla, Fernando Aranda, Lorenzo Galluzzi et al. (4 authors)
Current Opinion in Immunology
Published: Jun 2014
38 citations
38 citations
2550 days before retraction
New Agents and New Targets for Renal Cell Carcinoma
George Philips, Michael B. Atkins
American Society of Clinical Oncology Educational Book
Open Access
Published: May 2014
29 citations
29 citations
2598 days before retraction
Sunitinib resistance in renal cell carcinoma
Christudas Morais
Journal of Kidney Cancer and VHL
Open Access
Published: Apr 2014
62 citations
62 citations
2607 days before retraction
Hampering Immune Suppressors
Sabrin Albeituni, Chuanlin Ding, Jun Yan
The Cancer Journal
Open Access
Published: Nov 2013
65 citations
65 citations
2779 days before retraction
Quick Stats
Total Citations:
35
Years Since Retraction:
4.4 years
Open Access:
Yes
Last Checked:
Jul 24, 2025